Agios Pharmaceuticals Secures FDA Approval for Aqvesme (Mitapivat) in Thalassemia Treatment
Agios Pharmaceuticals; FDA approval; thalassemia; Aqvesme; mitapivat; anemia
Biohaven’s BHV-7000 Ion Channel Drug Fails Phase 2 Trial in Major Depressive Disorder
Biohaven; BHV-7000; major depressive disorder; phase 2 failure; Kv7 activator; psychiatric trials
Genmab Discontinues Phase III Development of Acasunlimab Lung Cancer Asset Previously Ditched by BioNTech
Genmab; acasunlimab; BioNTech; lung cancer; NSCLC; Phase 3; pipeline review
Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta
Ultragenyx; Mereo BioPharma; setrusumab; osteogenesis imperfecta; clinical trial failure; stock crash; bone mineral density
Vanda Pharmaceuticals Secures FDA Approval for NEREUS (Tradipitant), First New Motion Sickness Drug in Over 40 Years
Vanda Pharmaceuticals; FDA approval; NEREUS; tradipitant; motion sickness; vomiting prevention
FDA Rejects Relacorilant for Cushing’s Syndrome High Blood Pressure
FDA; relacorilant; Cushing’s syndrome; Corcept Therapeutics; rejection; high blood pressure
AbbVie Partners with China’s Zelgen on DLL3-Targeted T-Cell Engager ZG006 in Up-to-$1.2B Deal
AbbVie; Zelgen; ZG006; Alveltamig; DLL3; T-cell engager; small cell lung cancer; licensing deal
Insilico Medicine Caps 2025 with Record HKD 2.277 Billion Hong Kong IPO
Insilico Medicine; Hong Kong IPO; AI biotech; HKEX listing; drug discovery
FDA Policy Tracker: 2025 Was a Year of Change
FDA; 2025; Trump Administration; Food Safety; FSMA 204; GRAS Reform; Drug Approvals; Recall Improvements
Innovative Solutions for Difficult-to-Express Proteins: Cell-Free Systems and AI-Driven Advances
cell-free protein expression; difficult-to-express proteins; AI protein design; in vitro expression; alternative proteins